Dongqing Zuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongqing Zuo has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Haoran Mu
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Yingqi Hua
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
3 shared publications Haoyu Wang
Institute for Data-Driven Tumor Immunology, Chongqing Medical University, Chongqing, China
2 shared publications- Wei Sun
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Yu Lv
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications Zhengdong Cai
2 shared publications
Latest Publications
- Open Access
- 16 October 2025
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 55, 346-359
Targeting MAT2A synergistically induces DNA damage in osteosarcoma cells through EZH2-mediated H3K27me3 modification
- 16 October 2025
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 55, 346-359
Open AccessTargeting MAT2A synergistically induces DNA damage in osteosarcoma cells through EZH2-mediated H3K27me3 modification
- Open Access
- 19 October 2022
- Published by MDPI AG in Micromachines
- Vol. 13 (10) , 1780
Applications of Nano/Micromotors for Treatment and Diagnosis in Biological Lumens
Natural biological lumens in the human body, such as blood vessels and the gastrointestinal tract, are important to the delivery of materials. Depending on the anatomic features of these biological lumens, the invention of nano/micromotors could automatically locomote targeted sites for disease treatment and diagnosis. These nano/micromotors are designed to utilize chemical, physical, or even hybrid power in self-propulsion or propulsion by external forces. In this review, the research progress of nano/micromotors is summarized with regard to treatment and diagnosis in different biological lumens. Challenges to the development of nano/micromotors more suitable for specific biological lumens are discussed, and the overlooked biological lumens are indicated for further studies.
- 19 October 2022
- Published by MDPI AG in Micromachines
- Vol. 13 (10) , 1780
Open AccessApplications of Nano/Micromotors for Treatment and Diagnosis in Biological Lumens
Natural biological lumens in the human body, such as blood vessels and the gastrointestinal tract, are important to the delivery of materials. Depending on the anatomic features of these biological lumens, the invention of nano/micromotors could automatically locomote targeted sites for disease treatment and diagnosis. These nano/micromotors are designed to utilize chemical, physical, or even hybrid power in self-propulsion or propulsion by external forces. In this review, the research progress of nano/micromotors is summarized with regard to treatment and diagnosis in different biological lumens. Challenges to the development of nano/micromotors more suitable for specific biological lumens are discussed, and the overlooked biological lumens are indicated for further studies.
- Open Access
- 23 August 2021
- Published by Springer Nature in Research Square
Resection and Reconstruction of Acetabular Tumors involving Ischium and Inferior pubic bone with a Total Hip Replacement Using Posterior K-L Approach
Background: To explore the feasibility and short-term effect of posterior K-L (Kocher Langenbeek) approach in treating pelvic acetabular tumors involving ishium, inferior ramus of pubis. Methods: We retrospectively reviewed patients with acetabular tumors involving ishium, inferior ramus of pubis underwent surgery in Shanghai General Hospital from January 2016 to June 2020 with modified K-L approach, including 8 women and 12 men, patients aged from 19-76 years, including 6 chondrosarcomas, 6 osteosarcomas, 3 metastatic pelvic tumors, 2 epithelioid sarcomas, 3 giant cell tumor of bone. 20 patients were defined as pelvic Ennecking zone II + pelvic zone III involvement. All patients were followed up regularly in clinic, operation time, intraoperative bleeding, methods of reconstruction, duration of hospitalization, perioperative complications were recorded, and MSTS functional score was used to evaluate the patients' functional status.Results: All patients were followed up regularly in clinic with a mean 32 months (20-48 months). No patient died in the perioperative period, the average intraoperative bleeding was 1250 ml (800-2400 ml) in 10 patients, the mean operation duration was 2.6 hours (2-3.5 hours), no wound infection and delayed healing, the average duration of hospital stay was 12 days (10-16 days), the main complications during the follow-up included nervus cutaneus femoris posterior paralysis, 2 tumor recurrence, MSTS score was 22.5 points. 4 patients died during follow-up. Conclusions: The posterior K-L approach can be employed to effectively resect and reconstruction pelvic acetabular tumors invoving ishium, inferior ramus of pubis and reconstruct them properly. It is mainly suitable for malignant pelvic tumors involving the pelvic III and II + III regions. It also can often be available for biological reconstruction by using the acetabulum tantalum metal block, acetabulum reinforcing ring or autograft femur head. It is of highly safety and few perioperative complications, which is worth popularizing.
- 23 August 2021
- Published by Springer Nature in Research Square
Open AccessResection and Reconstruction of Acetabular Tumors involving Ischium and Inferior pubic bone with a Total Hip Replacement Using Posterior K-L Approach
Background: To explore the feasibility and short-term effect of posterior K-L (Kocher Langenbeek) approach in treating pelvic acetabular tumors involving ishium, inferior ramus of pubis. Methods: We retrospectively reviewed patients with acetabular tumors involving ishium, inferior ramus of pubis underwent surgery in Shanghai General Hospital from January 2016 to June 2020 with modified K-L approach, including 8 women and 12 men, patients aged from 19-76 years, including 6 chondrosarcomas, 6 osteosarcomas, 3 metastatic pelvic tumors, 2 epithelioid sarcomas, 3 giant cell tumor of bone. 20 patients were defined as pelvic Ennecking zone II + pelvic zone III involvement. All patients were followed up regularly in clinic, operation time, intraoperative bleeding, methods of reconstruction, duration of hospitalization, perioperative complications were recorded, and MSTS functional score was used to evaluate the patients' functional status.Results: All patients were followed up regularly in clinic with a mean 32 months (20-48 months). No patient died in the perioperative period, the average intraoperative bleeding was 1250 ml (800-2400 ml) in 10 patients, the mean operation duration was 2.6 hours (2-3.5 hours), no wound infection and delayed healing, the average duration of hospital stay was 12 days (10-16 days), the main complications during the follow-up included nervus cutaneus femoris posterior paralysis, 2 tumor recurrence, MSTS score was 22.5 points. 4 patients died during follow-up. Conclusions: The posterior K-L approach can be employed to effectively resect and reconstruction pelvic acetabular tumors invoving ishium, inferior ramus of pubis and reconstruct them properly. It is mainly suitable for malignant pelvic tumors involving the pelvic III and II + III regions. It also can often be available for biological reconstruction by using the acetabulum tantalum metal block, acetabulum reinforcing ring or autograft femur head. It is of highly safety and few perioperative complications, which is worth popularizing.
- Open Access
- 13 July 2021
- Published by Springer Nature in Research Square
TPX2 Promotes the Proliferation and Metastasis of Osteosarcoma Cells Through Stabilizing E2F1
Background: Osteosarcoma (OS) is the most common malignant bone cancer. Recently, more studies have shown that TPX2, a potential oncogene considered to be an important prognostic biomarker, is widely expressed in various tumors. However, until now, little is known about the impacts of TPX2 on the pathogenesis of OS.Methods: TPX2 expression of in OS cells and tissues was detected by Western blot and immunohistochemical analyses. Various assays were used to analyze OS cell proliferation and metastasis in vitro and in vivo. The effect of TPX2 on the expression of E2F1 and proteins encoded by E2F1-regulated genes was evaluated by Western blotting. Coimmunoprecipitation, immunofluorescence and in vitro ubiquitination assays were employed to explore the molecular mechanisms underlying the effect of TPX2 on stabilizing E2F1 and maintaining E2F1 signaling.Results: TPX2 is overexpressed in OS and is significantly correlated with the malignant progression of OS. TPX2 probably plays a critical role in the proliferation and metastasis of OS cells in vitro. Furthermore, TPX2 regulates E2F1 signaling by affecting the stability of E2F1, thereby affecting the proliferation and metastasis of OS cells. In addition, PSMD14 impacts the degradation and regulates the stability of E2F1. Most importantly, TPX2 regulates the interaction of E2F1 and PSMD14 to influence E2F1 degradation.Conclusions: Our research not only identifies TPX2 as a promising therapeutic target in cancer but also illuminates its underlying molecular mechanism. We showed that TPX2 promotes the malignant progression of OS by regulating E2F1 signaling.
- 13 July 2021
- Published by Springer Nature in Research Square
Open AccessTPX2 Promotes the Proliferation and Metastasis of Osteosarcoma Cells Through Stabilizing E2F1
Background: Osteosarcoma (OS) is the most common malignant bone cancer. Recently, more studies have shown that TPX2, a potential oncogene considered to be an important prognostic biomarker, is widely expressed in various tumors. However, until now, little is known about the impacts of TPX2 on the pathogenesis of OS.Methods: TPX2 expression of in OS cells and tissues was detected by Western blot and immunohistochemical analyses. Various assays were used to analyze OS cell proliferation and metastasis in vitro and in vivo. The effect of TPX2 on the expression of E2F1 and proteins encoded by E2F1-regulated genes was evaluated by Western blotting. Coimmunoprecipitation, immunofluorescence and in vitro ubiquitination assays were employed to explore the molecular mechanisms underlying the effect of TPX2 on stabilizing E2F1 and maintaining E2F1 signaling.Results: TPX2 is overexpressed in OS and is significantly correlated with the malignant progression of OS. TPX2 probably plays a critical role in the proliferation and metastasis of OS cells in vitro. Furthermore, TPX2 regulates E2F1 signaling by affecting the stability of E2F1, thereby affecting the proliferation and metastasis of OS cells. In addition, PSMD14 impacts the degradation and regulates the stability of E2F1. Most importantly, TPX2 regulates the interaction of E2F1 and PSMD14 to influence E2F1 degradation.Conclusions: Our research not only identifies TPX2 as a promising therapeutic target in cancer but also illuminates its underlying molecular mechanism. We showed that TPX2 promotes the malignant progression of OS by regulating E2F1 signaling.